{"id":744925,"date":"2014-09-17T07:30:00","date_gmt":"2014-09-17T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/"},"modified":"2023-03-22T00:04:51","modified_gmt":"2023-03-22T04:04:51","slug":"sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/","title":{"rendered":"Sun Pharma and Merck &#038; Co. Inc., Enter into Licensing Agreement for Tildrakizumab"},"content":{"rendered":"<p>\n      Merck &#038; Co., Inc., (NYSE:MRK), known as MSD outside the United States<br \/>\n      and Canada, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO,<br \/>\n      Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) through their<br \/>\n      respective subsidiaries, today announced an exclusive worldwide<br \/>\n      licensing agreement for Merck\u2019s investigational therapeutic antibody<br \/>\n      candidate, tildrakizumab, (MK-3222), which is currently being evaluated<br \/>\n      in Phase 3 registration trials for the treatment of chronic plaque<br \/>\n      psoriasis, a skin ailment.\n    <\/p>\n<p>\n      Under terms of the agreement, Sun Pharma will acquire worldwide rights<br \/>\n      to tildrakizumab for use in all human indications from Merck in exchange<br \/>\n      for an upfront payment of U.S. $80 million. Merck will continue all<br \/>\n      clinical development and regulatory activities, which will be funded by<br \/>\n      Sun Pharma. Upon product approval, Sun Pharma will be responsible for<br \/>\n      regulatory activities, including subsequent submissions,<br \/>\n      pharmacovigilance, post approval studies, manufacturing and<br \/>\n      commercialization of the approved product. Merck is eligible to receive<br \/>\n      undisclosed payments associated with regulatory (including product<br \/>\n      approval) and sales milestones, as well as tiered royalties ranging from<br \/>\n      mid-single digit through teen percentage rates on sales.\n    <\/p>\n<p>\n      \u201cConsistent with our previously announced global initiative to sharpen<br \/>\n      our commercial and R&#038;D focus, including prioritizing our late stage<br \/>\n      pipeline candidates, we are pleased to enter into this agreement with<br \/>\n      Sun Pharma to help realize the potential of tildrakizumab for patients<br \/>\n      with chronic plaque psoriasis,\u201d said Iain D. Dukes, Ph.D., senior vice<br \/>\n      president, Business Development and Licensing, Merck Research<br \/>\n      Laboratories.\n    <\/p>\n<p>\n      &#8220;Sun Pharma is very pleased to enter into this collaboration with Merck,<br \/>\n      a recognized leader in the field of inflammatory\/immunology therapies,<br \/>\n      for this late-stage candidate for chronic plaque psoriasis,\u201d said Kirti<br \/>\n      Ganorkar, senior vice president, Business Development, Sun Pharma. \u201cThis<br \/>\n      collaboration is a part of our strategy towards building our pipeline of<br \/>\n      innovative dermatology products in a market with strong growth<br \/>\n      potential.\u201d\n    <\/p>\n<p>\n      The transaction is subject to customary closing conditions, including<br \/>\n      the requirements under the Hart Scott-Rodino Antitrust Improvements Act.\n    <\/p>\n<p>\n      <b>About Tildrakizumab<\/b>\n    <\/p>\n<p>\n      Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal<br \/>\n      antibody that binds specifically to IL-23p19 and is therefore designed<br \/>\n      to selectively block the cytokine IL-23. Human genetics suggest that<br \/>\n      inhibiting IL-23 is effective for treating inflammatory conditions. In<br \/>\n      clinical studies for the treatment of chronic plaque psoriasis,<br \/>\n      tildrakizumab demonstrates efficacy in blocking inflammation by blocking<br \/>\n      IL-23. Other potential indications, which may be evaluated in future,<br \/>\n      include psoriatic arthritis and Crohn\u2019s Disease.\n    <\/p>\n<p>\n      Further details of the Phase 3 clinical trials can be found at: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fresults%3Fterm%3DMK-3222%26Search%3DSearch&#038;esheet=50944533&#038;newsitemid=20140917005589&#038;lan=en-US&#038;anchor=http%3A%2F%2Fclinicaltrials.gov&#038;index=1&#038;md5=2a27ca871fb9570a5697b9d1d81aae4e\" rel=\"nofollow\">http:\/\/clinicaltrials.gov<\/a>\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&#038;esheet=50944533&#038;newsitemid=20140917005589&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=6b16f70a9ba3447ddf7b184a68fa5b15\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2Fmerck&#038;esheet=50944533&#038;newsitemid=20140917005589&#038;lan=en-US&#038;anchor=Twitter&#038;index=3&#038;md5=794fbd2faf5598035c5c2a6f39257982\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2Fmerckbewell&#038;esheet=50944533&#038;newsitemid=20140917005589&#038;lan=en-US&#038;anchor=Facebook&#038;index=4&#038;md5=80d948e063d46459d49defb4298eeff6\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2Fmerck&#038;esheet=50944533&#038;newsitemid=20140917005589&#038;lan=en-US&#038;anchor=YouTube&#038;index=5&#038;md5=6999aa4b4cdbc7da0f29e92ee1f881d8\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>About Sun Pharma<\/b>\n    <\/p>\n<p>\n      Established in 1983, listed since 1994 and headquartered in India, Sun<br \/>\n      Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN,<br \/>\n      NSE: SUNPHARMA, BSE: 524715) is an international specialty<br \/>\n      pharmaceutical company with over 75% sales from global markets. It<br \/>\n      manufactures and markets a large basket of pharmaceutical formulations<br \/>\n      as branded generics as well as generics in US, India and several other<br \/>\n      markets across the world. For the year ending March 2014, overall<br \/>\n      revenues were at US$2.7 billion, of which US contributed US$1.6 billion.<br \/>\n      In India, the company is a leader in niche therapy areas of psychiatry,<br \/>\n      neurology, cardiology, nephrology, gastroenterology, orthopedics and<br \/>\n      ophthalmology. The company has strong skills in product development,<br \/>\n      process chemistry, and manufacturing of complex dosage forms. More<br \/>\n      information about the company can be found at <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sunpharma.com&#038;esheet=50944533&#038;newsitemid=20140917005589&#038;lan=en-US&#038;anchor=www.sunpharma.com&#038;index=6&#038;md5=1bf66890b03751840f6f54173c44c3b7\" rel=\"nofollow\">www.sunpharma.com<\/a>.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50944533&#038;newsitemid=20140917005589&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=7&#038;md5=444417a66fb130592cec101cbeb92508\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140917005589r2&#038;sid=hq1sc1&#038;distro=nx&#038;lang=en\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20140917005589\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20140917005589\/en\/<\/a><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908- 423-3046<br \/>Investor:<br \/>Justin        Holko, 908-423-5088<br \/>or<br \/>Sun Pharma<br \/>Media:<br \/>Frederick        Castro, +91-22-66455964<br \/>Investor:<br \/>Nimish Desai, +91-22-66455717     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &#038; Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck\u2019s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of U.S. $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-744925","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sun Pharma and Merck &amp; Co. Inc., Enter into Licensing Agreement for Tildrakizumab - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sun Pharma and Merck &amp; Co. Inc., Enter into Licensing Agreement for Tildrakizumab - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck\u2019s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of U.S. $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/\",\"name\":\"Sun Pharma and Merck & Co. Inc., Enter into Licensing Agreement for Tildrakizumab - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en\",\"datePublished\":\"2014-09-17T07:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Sun Pharma and Merck &#038; Co. Inc., Enter into Licensing Agreement for Tildrakizumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sun Pharma and Merck & Co. Inc., Enter into Licensing Agreement for Tildrakizumab - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/","og_locale":"en_US","og_type":"article","og_title":"Sun Pharma and Merck & Co. Inc., Enter into Licensing Agreement for Tildrakizumab - Merck.com","og_description":"Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) through their respective subsidiaries, today announced an exclusive worldwide licensing agreement for Merck\u2019s investigational therapeutic antibody candidate, tildrakizumab, (MK-3222), which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of U.S. $80 million. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:51+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/","name":"Sun Pharma and Merck & Co. Inc., Enter into Licensing Agreement for Tildrakizumab - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en","datePublished":"2014-09-17T07:30:00+00:00","dateModified":"2023-03-22T04:04:51+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140917005589r2&sid=hq1sc1&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/sun-pharma-and-merck-co-inc-enter-into-licensing-agreement-for-tildrakizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Sun Pharma and Merck &#038; Co. Inc., Enter into Licensing Agreement for Tildrakizumab"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"adf4913c-b71b-4588-a642-e56489b67f4f","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/09\/1\/logo_merck-logo.jpg","size":"13027","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2014\/09\/1\/sun-5B1-5D.jpg","size":"26458","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744925","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/744925\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=744925"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=744925"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}